Codexis, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Codexis, Inc. on July 17, 2022. The filing discloses a significant change in executive leadership, specifically the appointment of a new President and Chief Executive Officer (CEO) and the retirement of the incumbent CEO.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. The document focuses exclusively on executive compensation and employment terms.
Material Changes
The primary material change is the transition of CEO leadership effective August 9, 2022:
- Appointment: Dr. Stephen Dilly, a current Board member, was appointed President and CEO.
- Departure: John Nicols, the current President and CEO, will retire effective August 8, 2022.
- Board Changes: Mr. Nicols will remain on the Board until the 2023 Annual Meeting but will not stand for re-election. Byron Dorgan was appointed to the Audit Committee to fill the seat previously held by Dr. Dilly.
Compensation, Outlook, and Risks
New CEO Compensation (Dr. Dilly):
- Base Salary: $710,000 annually.
- Bonus: Target bonus of 75% of base salary.
- Sign-on Bonus: $200,000 (subject to clawback provisions).
- Equity: Option to purchase 700,000 shares and 340,000 performance stock units (up to 2 shares per unit).
- Benefits: $40,000 annual travel allowance and up to $20,000 legal fee reimbursement.
- Severance: 12 months of salary, bonus, and healthcare, plus accelerated equity vesting for termination without cause. In a change-in-control scenario, severance increases to 18 months with full equity acceleration.
Outgoing CEO Transition (Mr. Nicols):
- Role: Strategic Advisor through August 7, 2024.
- Compensation: $40,000/month for the first year; $20,000/month for the second year.
- Benefits: Three years of healthcare benefits and up to $35,000 legal fee reimbursement.
- Equity: Vesting ceases August 8, 2022; vested options remain exercisable for 3 months post-employment.
Risks and Contingencies: The filing notes that severance benefits for Dr. Dilly are conditioned on the execution of a general release of claims. The full terms of the agreements will be filed as exhibits to the Form 10-Q for the quarter ending September 30, 2022.
Investor Verification Checklist
- Verify the exact vesting schedule and performance metrics for Dr. Dilly's 340,000 performance stock units.
- Confirm the total cash outlay for the transition period, including Mr. Nicols' advisory fees and healthcare costs.
- Review the upcoming Form 10-Q for the full text of the Employment and Transition Agreements.
- Monitor the Board composition changes following the 2023 Annual Meeting of Stockholders.